<DOC>
	<DOC>NCT02675478</DOC>
	<brief_summary>This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.</brief_summary>
	<brief_title>Phase 1 Study of Quizartinib</brief_title>
	<detailed_description />
	<criteria>Relapsed or refractory AML AML for which no standard treatment is available ECOG Performance Status (PS) of 0 to 2 Acute Promyelocytic Leukemia chronic myelogenous leukemia in blast phase (BCRABL fusion gene positive) History of other malignancies within 3 years prior to enrollment, except curatively treated insitu carcinoma, AML, or MDS.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
</DOC>